

CIRM Funded Clinical Trials

A phase I trial of intratumoral administration of CCL21-gene modified dendritic cell (DC) combined with intravenous pembrolizumab for advanced NSCLC

Disease Area:	Lung Cancer
Investigator:	Steven Dubinett
Institution:	University of California, Los Angeles
CIRM Grant:	CLIN2-10784 (Pre-Active)
Award Value:	\$11,815,315
Trial Sponsor:	University of California, Los Angeles
Trial Stage:	Phase 1
Trial Status:	Launching
Targeted Enrollment:	N/A



Steven Dubinett

Details:

The five-year survival rate for people diagnosed with the most advanced stage of non-small cell lung cancer (NSCLC) is between one and 10 percent.

To address this devastating condition, UCLA researchers are genetically modifying a patient's own dendritic cells – key cells of the immune system – to boost their ability to stimulate native T cells - a type of white blood cell - to destroy cancer cells.

The investigators will combine this cell therapy with the FDA-approved therapy pembrolizumab (better known as Keytruda) a therapeutic that renders cancer cells more susceptible to clearance by the immune system.

Design:

Dose escalation and expansion.

Goal:

Determination of maximum tolerated dose and objective response rate at selected dose in lung cancers.

News Releases:

Clinical Trial Targeting Lung Cancer, Plus Promising Osteoporosis and Incontinence Research get Support from Stem Cell Agency